Journal
LEUKEMIA & LYMPHOMA
Volume 52, Issue 3, Pages 394-399Publisher
INFORMA HEALTHCARE
DOI: 10.3109/10428194.2010.546015
Keywords
-
Categories
Funding
- Canadian Cancer Society
- Ortho Biotech
Ask authors/readers for more resources
Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients were eligible if they had relapsed MCL with 1--3 prior therapies. Patients were treated with gemcitabine 1000 mg/m
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available